This site is intended for Healthcare Professionals outside the US

JAKAVI relieved burdensome symptoms of PV and improved quality of life (QoL)1-3

Provided consistent, clinically meaningful improvement of the most commonly reported PV symptoms1,2

Change in symptom scores (MPN-SAF) from baseline to Week 321

Polycythemia Vera treatment with JAK2 inhibitor, JAKAVI, provided rapid relief from pruritus and other symptoms
  • Change in symptom scores at Week 32 was an exploratory endpoint4

JAKAVI provided rapid and sustained relief of pruritus4

  • More than 4 times as many patients receiving JAKAVI reported that pruritus was "much improved" or "very much improved" compared with those receiving BAT4
    • 40% with JAKAVI vs 9.9% with BAT at Week 4
    • 58.2% with JAKAVI vs 12.5% with BAT at Week 32

JAKAVI provided clinically meaningful improvement of health-related QoL3

Global health status/quality-of-life score (EORTC QLQ-C30) over time3

JAKAVI provided clinically meaningful improvement of health-related quality of life for Polycythemia Vera patients
  • Change in EORTC QLQ-C30 score at each visit was an exploratory endpoint4
  • JAKAVI improved QoL across EORTC QLQ-C30 functional domains3
    • Role functioning
    • Physical functioning
    • Emotional functioning
    • Cognitive functioning
    • Social functioning

Improvements with JAKAVI were seen as soon as Week 4, maintained at least through Week 32, and observed across functional domains3

Next: Reduced spleen volume with JAKAVI

BAT=best available therapy; EORTC QLQ-C30=European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; MPN-SAF=The Myeloproliferative Neoplasm Symptom Assessment Form; TSS=total symptom score.


  1. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426-435.
  2. JAKAVI® (ruxolitinib) tablets: EU Summary of Product Characteristics. Novartis; May 2019.
  3. Mesa R, Verstovsek S, Kiladjian J-J, et al. Changes in quality of life and disease related symptoms in patients with polycythemia vera receiving ruxolitinib or best available therapy: RESPONSE trial results. Paper presented at: 56th ASH Annual Meeting and Exposition; December 6-9, 2014; San Francisco, CA.
  4. Data on file. Novartis Pharma AG. Basel, Switzerland.